BSBE(300406)2019-04-25 16:00Financial Performance - Total revenue for Q1 2019 was ¥172,243,979.14, representing a 5.52% increase compared to ¥163,225,957.30 in the same period last year[8] - Net profit attributable to shareholders for Q1 2019 was ¥60,239,351.39, up 4.03% from ¥57,904,330.97 in the previous year[8] - The company's operating revenue for Q1 2019 reached 172.24 million yuan, a 5.52% increase from 163.23 million yuan in the same period last year[26] - Net profit attributable to shareholders was 60.24 million yuan, up 4.03% from 57.90 million yuan year-on-year[26] - The net profit for the current period reached ¥59,203,965.21, reflecting a growth of 6.3% from ¥55,840,350.43 in the previous period[83] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 68.69%, totaling ¥7,612,566.71 compared to ¥24,312,071.01 in the same period last year[8] - Cash and cash equivalents increased by 46.38 million yuan, compared to a decrease of 17.85 million yuan in the same period last year, marking a 359.88% increase[26] - The cash flow from operating activities was ¥7,612,566.71, a decrease of 68.7% compared to ¥24,312,071.01 in the previous period[90] - The company reported cash and cash equivalents at the end of the period amounting to ¥526,495,469.67, down from ¥600,245,309.95 in the previous period[95] - The net increase in cash and cash equivalents for the current period was 78,527,342.67 in the previous period[101] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,845,885,780.61, a decrease of 1.01% from ¥1,864,725,364.65 at the end of the previous year[8] - Total current assets decreased to ¥1,244,820,722.50 as of March 31, 2019, from ¥1,271,477,190.70 as of December 31, 2018, representing a decline of approximately 2.0%[52] - Total liabilities decreased to ¥79,089,666.54 as of March 31, 2019, from ¥162,522,829.09 as of December 31, 2018, a significant reduction of approximately 51.3%[55] - Total equity increased to ¥1,735,247,004.34 from ¥1,671,688,812.01, showing a growth of 3.8%[67] Business Operations - The company's main business, in vitro diagnostic reagents, accounted for 92.43% of total revenue in Q1 2019, indicating a strong reliance on this segment[12] - The company faces intensified competition in the in vitro diagnostic industry, particularly in biochemical, immunological, and molecular diagnostics[12] - The company plans to enhance its competitiveness by increasing investment in new product development and expanding its marketing network[12] - The domestic in vitro diagnostic market is expected to maintain a high growth trend, driven by long-term demand for medical services[12] Research and Development - The company applied for 7 new patents and has 39 new products in the registration process during the reporting period[27] - Research and development expenses for the current period were ¥17,827,530.70, up from ¥15,606,231.38, marking a 14.1% increase[72] - Research and development expenses increased to ¥16,678,466.28, up 14.3% from ¥14,593,194.19 in the previous period[83] Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 14,661, with the top ten shareholders holding significant stakes, including Liu Xi at 13.35% and Luo Aiping at 12.14%[15] Other Financial Metrics - The company's interest receivables decreased by 86.27% year-on-year, from 2.8688 million RMB at the beginning of the period to 393,800 RMB at the end of the period, due to the expiration of certain fixed deposits[22] - Other current assets saw a significant decrease of 95.64% year-on-year, from 127.6279 million RMB to 5.5636 million RMB, mainly due to the expiration of fixed deposits[22] - The company reported a gross profit of ¥70,278,416.71, which is a 5.9% increase from the previous period[75] - The total amount of cash paid for purchasing goods and services was 79.80 million yuan, a 39.24% increase from 57.31 million yuan year-on-year[26]